Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZOSANO PHARMA CORPORATION

(ZSAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zosano Pharma : Corporate Presentation July 2021

07/19/2021 | 01:22pm EST

Corporate Presentation

July 2021

Copyright © 2021 Zosano Pharma Inc. | Confidential

1

Forward-Looking Statements

This presentation contains forward-looking statements regarding Zosano's technology and product candidates, including M207, Zosano's plans for and the anticipated timing with respect to the commencement of the PK study and the availability of data from the study, the expected timing of the resubmission of the M207 NDA to the FDA, the potential benefits and availability of M207 for patients, and other future events and expectations.

Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include, without limitation, risks and uncertainties associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and its periodic reports filed with the Securities and Exchange Commission. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Copyright © 2021 Zosano Pharma Inc. | Confidential

2

Zosano Pharma: Working to Transform How Drugs Are Delivered

Differentiated

Technology

Significant

Clinical

Evidence

Versatile

Platform

OUR MISSION

Advancing Patient Care and Transforming

Patient Lives Through Therapies Developed

Utilizing Our Proprietary Delivery Platform

OUR FOCUS

Late Stage Clinical Development Program for the Acute Treatment of Migraine Where Current Therapies Have Significant Limitations

OUR FUTURE

Patch Technology Designed to Allow for Innovative Application of Proteins, Peptides and Vaccines

Copyright © 2021 Zosano Pharma Inc. | Confidential

3

Executive Summary and Recent Developments

Transformative

Technology (formerly MACROFLUX) Developed at ALZA Corp/J&J

26 Patent Families and IP Protection

Delivery Platform

First and Only Microneedle Patch to be Included in an NDA Submission to the

FDA

Addressing

Migraine is Ranked Globally as the Seventh Most Disabling Disease1

Migraine Impacts approximately 37 Million People in the US2

Significant Unmet

M207, if Approved, May Have the Potential to Offer Fast, Complete and a

Needs in Migraine

Durability of Effect to Patients Suffering From Migraine3

Mitsubishi Tanabe Feasibility Study Agreement in August 2020

Partnerships

Two Additional Feasibility Studies Signed with Undisclosed Partners in Q4 2020

Actively Seeking Collaborations that Utilize our Proprietary Transdermal

Microneedle Patch Technology

Initiated Pharmacokinetic (PK) Study in June 2021 to Support Resubmission of the

Key Developments

M207 NDA

Eversana Commercialization Partnership - Commercial Services Valued at

Approximately $250MM Over 5 Years, if M207 is Approved

1. Steiner TJ et al. Migraine: the seventh disabler. The Journal of Headache and Pain 2013, 14:1. 2. American Migraine Foundation (2019) Migraine Essentials: What It's Like Living with Migraine. Retrieved from https://americanmigrainefoundation.org/living -with-migraine/migraine-essentials. 3. Spierings ELH et al. Randomized, double-blind,placebo-controlled,parallel-group,multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia 2018 Feb;38(2):215-224.

4

Zosano's Transdermal Drug Delivery

Novel & Proprietary

Transdermal patch with drug-coated microneedle array

Designed to be Rapid & Consistent

Designed for rapid and consistent absorption of drugs into capillary bed

Designed to Minimize Application Site Sensation

Shallow penetration designed to minimize stimulation of nerve endings

Convenient & Discreet

Quarter size patch with nickel sized array (~2,000 microneedles)

Designed to be Easy to Use

Substantial patient experience in clinical trials

Copyright © 2021 Zosano Pharma Inc. | Confidential

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Zosano Pharma Corporation published this content on 19 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 July 2021 17:21:06 UTC.


ę Publicnow 2021
All news about ZOSANO PHARMA CORPORATION
01/05Zosano Says Transdermal Microneedle Patch Matches High-Dose Intramuscular Injection in ..
MT
01/05ZOSANO PHARMA CORP : Other Events (form 8-K)
AQ
01/05Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogen..
AQ
01/05Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogen..
CI
2021ZOSANO PHARMA CORP : Change in Directors or Principal Officers (form 8-K)
AQ
2021Zosano Pharma Corporation Announces Board Changes
CI
2021Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Busine..
AQ
2021ZOSANO PHARMA CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or..
AQ
2021Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
2021Zosano Pharma Says Its Microneedle Patch System Utilized With COVID-19 Vaccine Candidat..
MT
More news
Analyst Recommendations on ZOSANO PHARMA CORPORATION
More recommendations
Financials (USD)
Sales 2021 1,81 M - -
Net income 2021 -28,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,01x
Yield 2021 -
Capitalization 62,7 M 62,7 M -
Capi. / Sales 2021 34,6x
Capi. / Sales 2022 4,13x
Nbr of Employees 45
Free-Float 99,5%
Chart ZOSANO PHARMA CORPORATION
Duration : Period :
Zosano Pharma Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZOSANO PHARMA CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,53 $
Average target price 2,00 $
Spread / Average Target 278%
EPS Revisions
Managers and Directors
Steven Lo President, Chief Executive Officer & Director
Christine Matthews Chief Financial Officer
Donald J. Kellerman VP-Clinical Development & Medical Affairs
Mahmoud Ameri Vice President-Research & Development
Lu Liu Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
ZOSANO PHARMA CORPORATION12.72%63
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684